医药生物行业周报:全球首个双靶点减重药上市,持续关注GLP-1赛道机会

东海证券
Jun 30, 2025

(以下内容从东海证券《医药生物行业周报:全球首个双靶点减重药上市,持续关注GLP-1赛道机会》研报附件原文摘录)投资要点:市场表现:上周(06月23日-06月27日)医药生物板块整体上涨1.60%,在申万31个行业中排第24位,跑输沪深300指数0.35个百分点。当前医药生物板块PE估值为27.67倍,处于历史中低位水平,相对于沪深300的估值溢价为124%。子板块涨幅前三的为医疗服务(申万)、...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10